The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer
Group Young Researchers in Inflammatory … - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest
cancers in western countries. It is commonly diagnosed at advanced stages and most anti …
cancers in western countries. It is commonly diagnosed at advanced stages and most anti …
Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer?
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all
major cancers. We now know that a 'one-size-fits-all'approach when treating PDAC patients …
major cancers. We now know that a 'one-size-fits-all'approach when treating PDAC patients …
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
K Dorman, D Zhang, K Heinrich, L Reeh, L Weiss… - Targeted Oncology, 2023 - Springer
Background In pancreatic cancer, systemic treatment options in addition to chemotherapy
remain scarce, and so far only a small proportion of patients benefit from targeted therapies …
remain scarce, and so far only a small proportion of patients benefit from targeted therapies …
EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy
J Lundy, M Harris, J Zalcberg, A Zimet… - Frontiers in …, 2021 - frontiersin.org
Background Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death
and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle …
and lacks effective treatment options. Diagnostic endoscopic ultrasound-guided fine-needle …
Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination …
Background Prognosis in pancreatic ductal adenocarcinoma (PDAC) remains poor despite
improved systemic therapies and surgical techniques. The identification of biomarkers to …
improved systemic therapies and surgical techniques. The identification of biomarkers to …
[HTML][HTML] Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant …
AV Reddy, CS Hill, S Sehgal, D Ding… - Radiation Oncology …, 2021 - ncbi.nlm.nih.gov
Purpose The purpose of this study was to determine if somatic mutations are associated with
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …
clinical and pathologic outcomes in patients with borderline resectable pancreatic cancer …
NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer
According to molecular profiling studies, a considerable number of patients with pancreatic
cancer harbor potentially actionable mutations. However, there are limited relevant data …
cancer harbor potentially actionable mutations. However, there are limited relevant data …
Clinico-genomic findings, molecular docking, and mutational spectrum in an understudied population with breast cancer patients from KP, Pakistan
In this study, we report the mutational profiles, pathogenicity, and their association with
different clinicopathologic and sociogenetic factors in patients with Pashtun ethnicity for the …
different clinicopathologic and sociogenetic factors in patients with Pashtun ethnicity for the …
Adequacy of EUS–guided fine-needle aspiration and fine-needle biopsy for next-generation sequencing in pancreatic malignancies: A systematic review and meta …
Y Pan, T Ran, X Zhang, X Qin, Y Zhang… - Endoscopic …, 2024 - journals.lww.com
Methods PubMed, Embase, Cochrane Library, and Web of Science were searched from
database inception to November 11, 2023. The primary outcome was the proportion of …
database inception to November 11, 2023. The primary outcome was the proportion of …
[HTML][HTML] Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer
L Wang, W Li, Y Liu, C Zhang, W Gao… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Objective: To investigate the safety, efficacy, and prognosis of advanced gastric cancer
patients treated with molecular targeted drug therapy. Methods: A total of 200 patients with …
patients treated with molecular targeted drug therapy. Methods: A total of 200 patients with …